X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with Fulford India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs FULFORD INDIA - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

FULFORD INDIA 
   Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS FULFORD INDIA IPCA LABS/
FULFORD INDIA
 
P/E (TTM) x 29.4 398.8 7.4% View Chart
P/BV x 3.5 6.2 56.0% View Chart
Dividend Yield % 0.1 0.1 159.1%  

Financials

 IPCA LABS   FULFORD INDIA
EQUITY SHARE DATA
    IPCA LABS
Mar-18
FULFORD INDIA
Mar-14
IPCA LABS/
FULFORD INDIA
5-Yr Chart
Click to enlarge
High Rs695942 73.8%   
Low Rs400450 88.9%   
Sales per share (Unadj.) Rs260.2691.4 37.6%  
Earnings per share (Unadj.) Rs19.011.5 165.5%  
Cash flow per share (Unadj.) Rs33.115.4 215.2%  
Dividends per share (Unadj.) Rs1.002.00 50.0%  
Dividend yield (eoy) %0.20.3 63.5%  
Book value per share (Unadj.) Rs213.0380.0 56.1%  
Shares outstanding (eoy) m126.203.90 3,235.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.11.0 209.1%   
Avg P/E ratio x28.960.7 47.5%  
P/CF ratio (eoy) x16.645.3 36.6%  
Price / Book Value ratio x2.61.8 140.4%  
Dividend payout %5.317.4 30.2%   
Avg Mkt Cap Rs m69,1202,714 2,546.4%   
No. of employees `00013.30.4 2,985.1%   
Total wages/salary Rs m7,359505 1,457.2%   
Avg. sales/employee Rs Th2,477.46,073.0 40.8%   
Avg. wages/employee Rs Th555.21,137.4 48.8%   
Avg. net profit/employee Rs Th180.6100.7 179.4%   
INCOME DATA
Net Sales Rs m32,8362,696 1,217.8%  
Other income Rs m418125 333.3%   
Total revenues Rs m33,2542,822 1,178.5%   
Gross profit Rs m4,505-46 -9,708.6%  
Depreciation Rs m1,77715 11,692.8%   
Interest Rs m24010 2,528.4%   
Profit before tax Rs m2,90554 5,350.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m51110 5,324.0%   
Profit after tax Rs m2,39445 5,356.2%  
Gross profit margin %13.7-1.7 -797.3%  
Effective tax rate %17.617.7 99.5%   
Net profit margin %7.31.7 439.8%  
BALANCE SHEET DATA
Current assets Rs m19,4551,738 1,119.2%   
Current liabilities Rs m10,076545 1,849.8%   
Net working cap to sales %28.644.3 64.5%  
Current ratio x1.93.2 60.5%  
Inventory Days Days9848 202.0%  
Debtors Days Days674 1,555.3%  
Net fixed assets Rs m20,26012 170,248.7%   
Share capital Rs m25239 647.2%   
"Free" reserves Rs m26,6331,443 1,845.7%   
Net worth Rs m26,8861,482 1,814.1%   
Long term debt Rs m2,3400-   
Total assets Rs m41,1732,077 1,982.6%  
Interest coverage x13.16.7 195.0%   
Debt to equity ratio x0.10-  
Sales to assets ratio x0.81.3 61.4%   
Return on assets %6.42.6 245.2%  
Return on equity %8.93.0 295.2%  
Return on capital %10.84.3 250.0%  
Exports to sales %47.60-   
Imports to sales %14.924.5 60.8%   
Exports (fob) Rs m15,642NA-   
Imports (cif) Rs m4,884659 740.7%   
Fx inflow Rs m15,64217 90,942.4%   
Fx outflow Rs m4,884673 725.5%   
Net fx Rs m10,759-656 -1,640.1%   
CASH FLOW
From Operations Rs m3,41190 3,790.3%  
From Investments Rs m-1,354105 -1,294.5%  
From Financial Activity Rs m-1,304-14 9,248.9%  
Net Cashflow Rs m753181 417.3%  

Share Holding

Indian Promoters % 45.9 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 11.4 3.8 300.0%  
FIIs % 25.3 0.1 25,300.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 21.2 82.1%  
Shareholders   36,892 4,783 771.3%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   J.B.CHEMICALS  VENUS REMEDIES  STERLING BIOTECH  CADILA HEALTHCARE  SUVEN LIFE  

Compare IPCA LABS With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Finish Flat; IT and Pharma Stocks Witness Selling(Closing)

Share markets in India ended their trading session on a flattish note. Sectoral indices ended on a mixed note with stocks in the IT sector and pharma sector witnessing most of the selling pressure.

Related Views on News

IPCA LABS Announces Quarterly Results (1QFY19); Net Profit Down 423.6% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, IPCA LABS has posted a net profit of Rs 655 m (down 423.6% YoY). Sales on the other hand came in at Rs 9 bn (up 19.8% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (4QFY18); Net Profit Up 15.6% (Quarterly Result Update)

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, IPCA LABS has posted a net profit of Rs 513 m (up 15.6% YoY). Sales on the other hand came in at Rs 8 bn (up 17.6% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are You Among The 35% Parents Who Will Not Be Able To Finance Their Child's Future?(Outside View)

Nov 1, 2018

PersonalFN explains the importance of being prepared for your child's future.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Nov 14, 2018 03:35 PM

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE IPCA LABS WITH

MARKET STATS